Skip to main content
Figure 3 | BMC Infectious Diseases

Figure 3

From: Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B

Figure 3

Efficacy of KALSOME™10 in murine VL. Two month infected animals were treated with 3.5 mg/kg single dose (SD) and 7.5 mg/kg SD and double doses (DD) of KALSOME™10 in 200 μl of 0.02 M PBS through the tail vein. One month post treatment, LDA was performed for evaluating their efficacy. Parasite burdens (A andC) and weights (B andD) of liver and spleen show the changes at different doses with normal and infected mice. Data expressed as means ± SE for six mice per group and are representative of two independent experiments with similar results. ***P < 0.001.

Back to article page